NASDAQ:TARA Protara Therapeutics (TARA) Stock Price, News & Analysis $3.12 -0.02 (-0.64%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.12 0.00 (0.00%) As of 08/29/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protara Therapeutics Stock (NASDAQ:TARA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Protara Therapeutics alerts:Sign Up Key Stats Today's Range$3.08▼$3.2250-Day Range$2.78▼$3.4252-Week Range$1.60▼$10.48Volume83,675 shsAverage Volume177,100 shsMarket Capitalization$120.37 millionP/E RatioN/ADividend YieldN/APrice Target$19.60Consensus RatingBuy Company Overview Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. Read More Protara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreTARA MarketRank™: Protara Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 803rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingProtara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtara Therapeutics has received no research coverage in the past 90 days.Read more about Protara Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protara Therapeutics are expected to decrease in the coming year, from ($3.32) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protara Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protara Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtara Therapeutics has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Protara Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.29% of the float of Protara Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtara Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Protara Therapeutics has recently increased by 1.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtara Therapeutics does not currently pay a dividend.Dividend GrowthProtara Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.29% of the float of Protara Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtara Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Protara Therapeutics has recently increased by 1.38%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.76 News SentimentProtara Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows1 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Protara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 38.13% of the stock of Protara Therapeutics is held by institutions.Read more about Protara Therapeutics' insider trading history. Receive TARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARA Stock News HeadlinesProtara Therapeutics to Participate in Upcoming Investor ConferencesAugust 27 at 8:00 AM | globenewswire.comEquities Analysts Issue Forecasts for TARA FY2025 EarningsAugust 22, 2025 | americanbankingnews.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $19.60 Consensus Price Target from AnalystsAugust 22, 2025 | americanbankingnews.comWe're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateAugust 13, 2025 | finance.yahoo.comProtara Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comProtara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | gurufocus.comSee More Headlines TARA Stock Analysis - Frequently Asked Questions How have TARA shares performed this year? Protara Therapeutics' stock was trading at $5.28 at the start of the year. Since then, TARA shares have decreased by 40.9% and is now trading at $3.12. How were Protara Therapeutics' earnings last quarter? Protara Therapeutics, Inc. (NASDAQ:TARA) announced its earnings results on Monday, August, 11th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. Who are Protara Therapeutics' major shareholders? Top institutional investors of Protara Therapeutics include Velan Capital Investment Management LP (5.54%), Acorn Capital Advisors LLC (4.54%), Stempoint Capital LP (2.96%) and Opaleye Management Inc. (2.22%). Insiders that own company stock include Jacqueline Zummo and Opaleye Management Inc. View institutional ownership trends. How do I buy shares of Protara Therapeutics? Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Digital Turbine (APPS), SoFi Technologies (SOFI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD). Company Calendar Last Earnings8/11/2025Today8/29/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TARA CIK1359931 Webwww.proteontherapeutics.com Phone(646) 844-0337Fax781-487-6729Employees30Year FoundedN/APrice Target and Rating Average Price Target for Protara Therapeutics$19.60 High Price Target$23.00 Low Price Target$12.00 Potential Upside/Downside+528.2%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.87% Return on Assets-33.85% Debt Debt-to-Equity RatioN/A Current Ratio12.81 Quick Ratio12.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book0.83Miscellaneous Outstanding Shares38,582,000Free Float35,341,000Market Cap$120.38 million OptionableOptionable Beta1.42 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:TARA) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.